Trials / Completed
CompletedNCT00092040
A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 936 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- Female
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0217, alendronate sodium/Duration of Intervention: 12 mo | |
| DRUG | Comparator: risedronate / Duration of Intervention: 12 mo |
Timeline
- Start date
- 2003-03-18
- Primary completion
- 2004-10-18
- Completion
- 2005-09-28
- First posted
- 2004-09-24
- Last updated
- 2024-08-14
Source: ClinicalTrials.gov record NCT00092040. Inclusion in this directory is not an endorsement.